Gassis S, Rathod P K
Department of Biology, Catholic University of America, Washington, DC 20064, USA.
Antimicrob Agents Chemother. 1996 Apr;40(4):914-9. doi: 10.1128/AAC.40.4.914.
A combination of 5-fluoroorotate and atovaquone eliminated Plasmodium falciparum in long-term cultures more efficiently than either compound alone. The improved potency came not through synergistic activity but through decreased frequency of drug resistance. In support of this finding, it was shown that 5-fluoroorotate and atovaquone do not act in a synergistic fashion, that 5-fluoroorotate-resistant and atovaquone-resistant P. falciparum organisms generated in vitro do not show cross-resistance, and that the frequency of simultaneous resistance to the two compounds approached the product of their individual resistance frequencies. To demonstrate the last finding, and establish proof of principle, an in vitro method was developed for measuring the frequency of drug resistance in P. falciparum. By this method, it was shown that the frequency of resistance to 10(-7) M 5-fluoroorotate was about 10(-6) and the frequency of resistance to 10(-8) M atovaquone was about 10(-5); the frequency of simultaneous resistance to a combination of 10(-7) M 5-fluoroorotate and 10(-8) M atovaquone was less than 5 x 10(-10). On the basis of additional measurements, it was estimated that the frequency of simultaneous resistance to higher, pharmacologically more relevant, concentrations of 10(-6) M 5-fluoroorotate and 10(-7) M atovaquone would be less than 10(-17). Control experiments demonstrated that these drug combinations did not cause increased toxicity to mammalian cells in culture. On this basis, it is predicted that a combination of 5-fluoroorotate and atovaquone will successfully eliminate typical malarial infections in animals and in human patients at doses that are readily tolerated.
5-氟乳清酸和阿托伐醌联合使用在长期培养中比单独使用任何一种化合物都更有效地消除了恶性疟原虫。效力的提高并非通过协同活性,而是通过降低耐药频率。支持这一发现的是,研究表明5-氟乳清酸和阿托伐醌并非以协同方式起作用,体外产生的对5-氟乳清酸耐药和对阿托伐醌耐药的恶性疟原虫没有表现出交叉耐药性,并且对这两种化合物同时耐药的频率接近它们各自耐药频率的乘积。为了证明最后一个发现并建立原理证明,开发了一种体外方法来测量恶性疟原虫的耐药频率。通过这种方法,研究表明对10(-7) M 5-氟乳清酸的耐药频率约为10(-6),对10(-8) M阿托伐醌的耐药频率约为10(-5);对10(-7) M 5-氟乳清酸和10(-8) M阿托伐醌联合使用的同时耐药频率小于5×10(-10)。基于额外的测量,估计对更高、药理学上更相关浓度的10(-6) M 5-氟乳清酸和10(-7) M阿托伐醌同时耐药的频率将小于10(-17)。对照实验表明这些药物组合不会对培养中的哺乳动物细胞造成毒性增加。在此基础上,预计5-氟乳清酸和阿托伐醌联合使用将以易于耐受的剂量成功消除动物和人类患者的典型疟疾感染。